172 related articles for article (PubMed ID: 9156364)
21. Ex vivo relaxations of pulmonary arteries induced by prostacyclin mimetics are highly dependent of the precontractile agents.
Benyahia C; Ozen G; Orie N; Ledwozyw A; Louedec L; Li F; Senbel AM; Silverstein A; Danel C; Longrois D; Clapp LH; Norel X; Topal G
Prostaglandins Other Lipid Mediat; 2015 Sep; 121(Pt A):46-52. PubMed ID: 26362969
[TBL] [Abstract][Full Text] [Related]
22. Prostanoid action on the human pulmonary vascular system.
Jones RL; Qian Y; Wong HN; Chan H; Yim AP
Clin Exp Pharmacol Physiol; 1997 Dec; 24(12):969-72. PubMed ID: 9406667
[TBL] [Abstract][Full Text] [Related]
23. Potent contractile actions of prostanoid EP3-receptor agonists on human isolated pulmonary artery.
Qian YM; Jones RL; Chan KM; Stock AI; Ho JK
Br J Pharmacol; 1994 Oct; 113(2):369-74. PubMed ID: 7834185
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of rat colon contractility by prostacyclin (IP-) receptor agonists: involvement of NANC neurotransmission.
Qian YM; Jones RL
Br J Pharmacol; 1995 May; 115(1):163-71. PubMed ID: 7544196
[TBL] [Abstract][Full Text] [Related]
25. Distinction between relaxations induced via prostanoid EP(4) and IP(1) receptors in pig and rabbit blood vessels.
Jones RL; Chan K
Br J Pharmacol; 2001 Sep; 134(2):313-24. PubMed ID: 11564649
[TBL] [Abstract][Full Text] [Related]
26. A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active form, {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid (MRE-269), on rat pulmonary artery.
Kuwano K; Hashino A; Noda K; Kosugi K; Kuwabara K
J Pharmacol Exp Ther; 2008 Sep; 326(3):691-9. PubMed ID: 18552131
[TBL] [Abstract][Full Text] [Related]
27. Evidence for a second receptor for prostacyclin on human airway epithelial cells that mediates inhibition of CXCL9 and CXCL10 release.
Wilson SM; Sheddan NA; Newton R; Giembycz MA
Mol Pharmacol; 2011 Mar; 79(3):586-95. PubMed ID: 21173040
[TBL] [Abstract][Full Text] [Related]
28. Differential actions of the prostacyclin analogues treprostinil and iloprost and the selexipag metabolite, MRE-269 (ACT-333679) in rat small pulmonary arteries and veins.
Orie NN; Ledwozyw A; Williams DJ; Whittle BJ; Clapp LH
Prostaglandins Other Lipid Mediat; 2013 Oct; 106():1-7. PubMed ID: 23872196
[TBL] [Abstract][Full Text] [Related]
29. Prostacyclin analogues differentially inhibit growth of distal and proximal human pulmonary artery smooth muscle cells.
Wharton J; Davie N; Upton PD; Yacoub MH; Polak JM; Morrell NW
Circulation; 2000 Dec; 102(25):3130-6. PubMed ID: 11120706
[TBL] [Abstract][Full Text] [Related]
30. Characterization of receptors involved in the direct and indirect actions of prostaglandins E and I on the guinea-pig ileum.
Lawrence RA; Jones RL; Wilson NH
Br J Pharmacol; 1992 Feb; 105(2):271-8. PubMed ID: 1559125
[TBL] [Abstract][Full Text] [Related]
31. Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension.
Falcetti E; Hall SM; Phillips PG; Patel J; Morrell NW; Haworth SG; Clapp LH
Am J Respir Crit Care Med; 2010 Nov; 182(9):1161-70. PubMed ID: 20622039
[TBL] [Abstract][Full Text] [Related]
32. Induction of hyaluronic acid synthase 2 (HAS2) in human vascular smooth muscle cells by vasodilatory prostaglandins.
Sussmann M; Sarbia M; Meyer-Kirchrath J; Nüsing RM; Schrör K; Fischer JW
Circ Res; 2004 Mar; 94(5):592-600. PubMed ID: 14752026
[TBL] [Abstract][Full Text] [Related]
33. Selective Prostacyclin Receptor Agonist Selexipag, in Contrast to Prostacyclin Analogs, Does Not Evoke Paradoxical Vasoconstriction of the Rat Femoral Artery.
Morrison K; Haag F; Ernst R; Iglarz M; Clozel M
J Pharmacol Exp Ther; 2018 Jun; 365(3):727-733. PubMed ID: 29588339
[TBL] [Abstract][Full Text] [Related]
34. Structure-activity relationships associated with 3,4,5-triphenyl-1H-pyrazole-1-nonanoic acid, a nonprostanoid prostacyclin mimetic.
Meanwell NA; Rosenfeld MJ; Wright JJ; Brassard CL; Buchanan JO; Federici ME; Fleming JS; Seiler SM
J Med Chem; 1992 Jan; 35(2):389-97. PubMed ID: 1370696
[TBL] [Abstract][Full Text] [Related]
35. Effects of isocarbacyclin, a stable prostacyclin analogue, on monkey isolated cerebral and peripheral arteries.
Kawai Y; Ohhashi T
Br J Pharmacol; 1994 Jun; 112(2):635-9. PubMed ID: 8075881
[TBL] [Abstract][Full Text] [Related]
36. Biochemical and pharmacological activity of arene-fused prostacyclin analogues on human platelets.
Jakubowski JA; Utterback BG; Mais DE; Hardinger SA; Braish TF; Nevill CR; Fuchs PL
Prostaglandins; 1994 Mar; 47(3):189-201. PubMed ID: 8016389
[TBL] [Abstract][Full Text] [Related]
37. TEI-9063, a stable and highly specific prostacyclin analogue for the prostacyclin receptor in mastocytoma P-815 cells.
Negishi M; Hashimoto H; Yatsunami K; Kurozumi S; Ichikawa A
Prostaglandins; 1991 Sep; 42(3):225-37. PubMed ID: 1723528
[TBL] [Abstract][Full Text] [Related]
38. Agonists can discriminate between cloned human and mouse prostacyclin receptors.
Chow KB; Jones RL; Wise H
Prostaglandins Leukot Essent Fatty Acids; 2004 May; 70(5):423-9. PubMed ID: 15062844
[TBL] [Abstract][Full Text] [Related]
39. EP4 prostanoid receptor-mediated vasodilatation of human middle cerebral arteries.
Davis RJ; Murdoch CE; Ali M; Purbrick S; Ravid R; Baxter GS; Tilford N; Sheldrick RL; Clark KL; Coleman RA
Br J Pharmacol; 2004 Feb; 141(4):580-5. PubMed ID: 14744815
[TBL] [Abstract][Full Text] [Related]
40. Evidence that Ca2+-activated K+ channels play a major role in mediating the vascular effects of iloprost and cicaprost.
Clapp LH; Turcato S; Hall S; Baloch M
Eur J Pharmacol; 1998 Sep; 356(2-3):215-24. PubMed ID: 9774252
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
